Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $10.1 million.

  • Voyager Therapeutics' Gains from Investment Securities rose 1359.06% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 1359.06%. This contributed to the annual value of $8.8 million for FY2024, which is 1851.77% up from last year.
  • Per Voyager Therapeutics' latest filing, its Gains from Investment Securities stood at $10.1 million for Q3 2025, which was up 1359.06% from $10.3 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Gains from Investment Securities peaked at $10.3 million during Q2 2025, and registered a low of -$2.8 million during Q4 2022.
  • For the 5-year period, Voyager Therapeutics' Gains from Investment Securities averaged around $4.3 million, with its median value being $5.9 million (2021).
  • As far as peak fluctuations go, Voyager Therapeutics' Gains from Investment Securities crashed by 361911.76% in 2021, and later skyrocketed by 9876.98% in 2023.
  • Over the past 5 years, Voyager Therapeutics' Gains from Investment Securities (Quarter) stood at -$2.5 million in 2021, then dropped by 12.5% to -$2.8 million in 2022, then soared by 98.77% to -$35000.0 in 2023, then increased by 8.57% to -$32000.0 in 2024, then soared by 31590.6% to $10.1 million in 2025.
  • Its last three reported values are $10.1 million in Q3 2025, $10.3 million for Q2 2025, and -$30000.0 during Q1 2025.